Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.56 |
| ▸ | CD69 | Q07108 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 10/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29676859 | 1.00 | BTK (0.56) | BTKCD69LMNAKMT2ABDKRB1 | |
| SCHEMBL16794448 | 1.00 | BTK (0.56) | BTKCD69LMNAKMT2ABDKRB1 | |
| SCHEMBL16794009 | 0.84 | BTK (0.56) | BTKCD69LMNAKMT2ACCR2 | |
| SCHEMBL29676706 | 0.84 | BTK (0.56) | BTKCD69LMNAKMT2ACCR2 | |
| SCHEMBL16794071 | 0.82 | BTK (0.43) | BTKCD69LMNAKMT2ABDKRB1 | |
| SCHEMBL16794065 | 0.79 | BTK (0.71) | BTKCD69 | |
| SCHEMBL29676632 | 0.78 | BTK (0.56) | BTKCD69LMNAKMT2ACCR2 | |
| SCHEMBL16794208 | 0.78 | BTK (0.56) | BTKCD69LMNAKMT2ACCR2 | |
| SCHEMBL20461142 | 0.78 | BTK (0.41) | BTKCD69LMNAKMT2ABDKRB1 | |
| SCHEMBL20461119 | 0.76 | BTK (0.46) | BTKCD69KMT2ABDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357921-A2 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | Sunesis Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |